US Conjugate Vaccine Market

US Conjugate Vaccines Market Research Report, By Type (Haemophilus B, Monovalent, Multivalent, And Others), Indication (Influenza, Pneumococcal, Meningococcal, And Others), End Users (Pediatrics And Adults) - Forecast Till 2032

ID: MRFR/Pharma/11305-CR | 100 Pages | Author: Garvit Vyas | December 2023         

The demand for conjugate vaccines in the United States is driven by several factors, reflecting the importance of these vaccines in preventing infectious diseases and reducing the burden on the healthcare system. Conjugate vaccines are a type of vaccine that uses a protein or polysaccharide antigen linked to a carrier protein to enhance the immune response. This makes them particularly effective in protecting against bacterial infections, including meningitis, pneumonia, and Haemophilus influenzae type b (Hib).


One of the key drivers of demand in the US conjugate vaccine market is the emphasis on preventive healthcare. Vaccination is widely recognized as one of the most cost-effective ways to prevent infectious diseases and their complications. Conjugate vaccines, with their ability to provide long-lasting immunity and reduce the spread of disease, are an important tool in preventing outbreaks and protecting vulnerable populations, such as infants, the elderly, and individuals with weakened immune systems.


The US conjugate vaccine market is segmented into various categories based on the type of vaccine and the target disease. Common types of conjugate vaccines include those for pneumococcal disease, meningococcal disease, and Hib. These vaccines are recommended for children as part of routine immunization schedules and are also used in certain high-risk populations, such as travelers to areas where these diseases are endemic.


The introduction of new vaccines and the expansion of immunization programs have contributed to the growth of the US conjugate vaccine market. For example, the introduction of the pneumococcal conjugate vaccine (PCV13) has led to a significant reduction in the incidence of pneumococcal disease, including pneumonia and invasive pneumococcal disease, in both children and adults. Similarly, the introduction of the meningococcal conjugate vaccine (MenACWY) has helped reduce the incidence of meningococcal disease, particularly among adolescents and young adults.


The US conjugate vaccine market is highly competitive, with several pharmaceutical companies offering a range of products to meet the diverse needs of healthcare providers and patients. Key players in the market include Pfizer, GlaxoSmithKline, Sanofi Pasteur, and Merck, among others. These companies invest heavily in research and development to introduce new conjugate vaccines and improve existing vaccines, driving further growth in the market.


In recent years, there has been a growing focus on expanding access to conjugate vaccines in the US. This includes efforts to increase vaccination rates among high-risk populations, such as infants and the elderly, as well as initiatives to improve vaccine coverage in underserved communities. These efforts are aimed at reducing the overall burden of infectious diseases in the US and improving public health outcomes.


Overall, the demand for conjugate vaccines in the US is expected to continue growing, driven by the emphasis on preventive healthcare, the introduction of new vaccines, and efforts to expand access to vaccination. As the healthcare system seeks to reduce the incidence of infectious diseases and improve population health, conjugate vaccines will remain a vital tool in achieving these goals.

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 6.80 Billion
  CAGR   7.3%
  Base Year   2021
  Forecast Period   2023-2032
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Vaccine, Serotype, End User and Region
  Geographies Covered   North America, Europe, Asia Pacific, and Rest of the World
  Key Vendors   Pfizer Inc (US), Novartis AG (Switzerland), Sanofi S.A.(France), Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Ltd (China), Bio-Manguinhos (Brazil)
  Key Market Opportunities   Increasing inclusion in national immunization programs
  Key Market Drivers   Increasing awareness and surge in travel vaccine Increase in R&D for vaccine technology




Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players‚Äô financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid